Solu Therapeutics is a biotechnology company cofounded by Longwood Fund and committed to developing an innovative class of therapeutic agents that uniquely pair small molecules with monoclonal antibodies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas. By leveraging its proprietary CyTAC (Cytotoxicity Targeting Chimera) and TicTAC (Therapeutic Index Control Targeting Chimera) platforms, Solu is advancing therapies that combine the target-binding capability of small molecules with the therapeutic power of biologics. Our lead product candidate, STX-0712, is currently in Phase 1 clinical development for the treatment of advanced hematologic malignancies including CMML.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/09/25 | $41,000,000 | Series A |
Alexandria Venture Investments Astellas Venture Management Biovision Ventures DCVC Bio Eli Lilly and Company Hengdian Group Capital Longwood Fund Pappas Capital Sante Ventures The Leukemia & Lymphoma Society | undisclosed |
